A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. 2002

John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
St. Jude Children's Research Hospital, 332 North Lauderdale St., Memphis, TN 38105-2794, USA.

Methotrexate (MTX) is one of the most widely used drugs for the treatment of childhood acute lymphoblastic leukemia (ALL). Interindividual differences in lymphoblast accumulation of MTX and its active metabolites, methotrexate polyglutamates (MTXPG), may contribute to the effectiveness of treatment among ALL subtypes. To better understand these differences in MTXPG accumulation, we developed a model to characterize the cellular influx and efflux of MTX, formation of MTXPG by the addition of glutamyl residues catalyzed by FPGS (folylpolyglutamate synthetase), and cleavage of glutamyl residues from MTXPG by GGH (gamma-glutamyl hydrolase). The model was fitted to in vivo intracellular MTXPG concentrations measured serially in leukemic blasts from 20 newly diagnosed patients with ALL treated with 24-h intravenous infusions of MTX. The observed median concentrations of total MTXPG at 44 h was higher in B-lineage than in T-cell ALL (1706 vs 518 pmol/10(9) cells, P<0.025), consistent with the higher estimated Vmax for FPGS activity in B-lineage vs T-lineage blasts (414 vs 93 pmol/10(9) cells/h, P<0.008). Simulations based on the model-estimated parameters indicated greater accumulation of MTX, MTXPGs (MTXPG(2-7)) and total MTX (MTXPG(1-7)) with longer MTX infusions and with higher MTX doses, with the highest concentrations in hyperdiploid B-lineage, intermediate in non-hyperdiploid B-lineage, and lowest in T-cell ALL. These differences provide mechanistic and treatment insights for lineage and ploidy differences in MTXPG accumulation in human leukemia cells in vivo.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011099 Polyglutamic Acid A peptide that is a homopolymer of glutamic acid. Polyglutamate
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D011623 gamma-Glutamyl Hydrolase Catalyzes the hydrolysis of pteroylpolyglutamic acids in gamma linkage to pterolylmonoglutamic acid and free glutamic acid. EC 3.4.19.9. Conjugase,Folate Conjugase,Folyl Conjugate Synthetase,Pteroyl Polyglutamate Hydrolase,Carboxypeptidase G,Carboxypeptidase G1,Carboxypeptidase G2,Folacin Conjugase,Folate Hydrolyzing Enzyme,Folyl Poly-gamma-Glutamate Carboxypeptidase,Folyl Polyglutamate Cleavage Enzyme,Folylpolyglutamate Hydrolase,gamma Glutamyl Hydrolase
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's

Related Publications

John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
July 2002, Clinical cancer research : an official journal of the American Association for Cancer Research,
John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
November 1994, The Journal of clinical investigation,
John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
December 2010, PLoS computational biology,
John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
January 2014, The Pan African medical journal,
John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
July 1990, Blood,
John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
July 2023, Pharmaceutical research,
John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
May 2007, Cancer chemotherapy and pharmacology,
John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
January 1981, Cancer treatment reports,
John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
December 2022, Turkish journal of haematology : official journal of Turkish Society of Haematology,
John Carl Panetta, and Yuri Yanishevski, and Ching-Hon Pui, and John T Sandlund, and Jeffrey Rubnitz, and Gaston K Rivera, and Raul Ribeiro, and William E Evans, and Mary V Relling
September 2015, The Journal of clinical investigation,
Copied contents to your clipboard!